MIMETAS, a leader in human-relevant organ-on-a-chip models, has opened their Phenotypic Screening Center. The centre facilitates large-scale screening campaigns on Organ-on-a-Chip models, a powerful technology that improves the human physiological relevance of cultured tissues by utilizing microfluidic techniques. In contrast to other Organ-on-a-Chip platforms, the MIMETAS OrganoPlate technology offers the scalability and the throughput needed for drug discovery studies.
The new screening centre is the first energy-neutral laboratory building in the Netherlands. It is located in the new head office of MIMETAS in Oegstgeest, the largest life sciences cluster in The Netherlands.
“We are very proud to open up this new centre,” said Jos Joore, CEO of MIMETAS. “Our new Phenotypic Screening Center facilitates high-throughput organ-on-a-chip screening combined with high-content imaging and machine learning data analysis to identify drug candidates for today’s unmet medical needs. Our customers understand that human-relevant disease models should be at the basis of every drug discovery effort. Moreover, these cutting-edge technologies stimulate the creativity and purpose of our scientists to make a difference in the lives of patients.”
Largest Organ-on-a-Chip compound screen
MIMETAS recently reported a successful 1,546 compound screen in duplicate on a 3D angiogenesis assay in the OrganoPlate 3-lane 64. Promising hit compounds from this screen are currently under investigation.
“To our knowledge, this is the largest organ-on-a-chip screen ever reported,” explained Joore. “We partner with large pharmaceutical companies, that need our disease model screening expertise, and can bring promising candidates to the clinic fast. In this way, we make sure that we bring novel drugs to patients in the most efficient manner.”